<div id="readability-page-1">RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances in the development of RHB-102 (Bekinda), a therapy aimed at addressing gastrointestinal side effects linked to widely used GLP-1/GIP weight-loss and diabetes drugs. The specialty biopharmaceutical group is progressing RHB-102—a once-daily oral formulation of ondansetron—through the U.S. Food […]</div>

Redhill生物制藥

<p>RedHill Biopharma Ltd.（納斯達克代碼：RDHL）在盤前交易中股價上漲了 16.5%，原因是該公司宣佈在開發 RHB-102（Bekinda）方面取得進展，該藥物旨在針對與 GLP-1/GIP 減肥和糖尿病藥物相關的胃腸道副作用。這家生物製藥公司正在通過美國監管流程推進 RHB-102，這是一種每日一次的口服昂丹司瓊製劑</p>

RedHill 生物製藥的股票因在治療 GLP-1 副作用方面取得進展而大幅上漲